Miriam Michael

Articles by Miriam Michael

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

144 A Comparative Analysis of Pregnancy-Related Breast Cancer Outcomes Versus Non-Pregnant Breast Cancer Patients—A TriNetX Real-World Analysis

ByUchenna M. Amaechi,Samrawit Zinabu,Chiugo Okoye,Oladayo Oyebanji,Chinemerem M. Emeasoba,Miriam Michael

April 29th 2026

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

ByUchenna M. Amaechi,Kenneth Ssebambulidde,Chiugo Okoye,Oladayo Oyebanji,Chinemerem M. Emeasoba,Miriam Michael

April 28th 2026

Latest Updated Articles

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis
April 28th 2026

Trending on CancerNetwork

Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy

CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial

Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma

Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3

Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC